IFNGR1 and neoplasm: Consistently, tumor-intrinsic IFNGR1 deficiency was associated with reduced therapeutic effects of CTLA-4 blockade, resulting in accelerated tumor growth and reduced survival of B16/BL6-bearing mice, indicating an association between the lack of tumor-intrinsic IFN-γ signaling and primary resistance to CTLA-4 blockade.